Trelagliptin succinate
|
|
Trelagliptin succinate 속성
- 저장 조건
- -20°C
- 용해도
- DMSO에 용해됨
- 물리적 상태
- 가루
- 색상
- 회백색 고체
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
그림문자(GHS): | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
신호 어: | Warning | |||||||||||||||||||||||||||||||||||
유해·위험 문구: |
|
|||||||||||||||||||||||||||||||||||
예방조치문구: |
|
Trelagliptin succinate C화학적 특성, 용도, 생산
개요
Similar to omarigliptin, trelagliptin succinate (XIX) is a highly selective, orally delivered inhibitor of DPP-4 developed by Takeda Pharmaceuticals and approved in Japan in March 2015 for the treatment of type 2 DM. Interestingly, trelagliptin is structurally similar to alogliptin, a DPP-4 inhibitor also marketed by Takeda and described in our 2010 review, differing only in the presence of a fluorine in the 5-position of the cyanobenzyl moiety. Both trelagliptin and alogliptin are potent inhibitors of DPP-4, with IC50s of 1.3 and 5.3 nM, respectively. Notably, while similar drugs are dosed once daily, trelagliptin is the first DPP-4 inhibitor approved for onceweekly dosing. Kinetic analysis has revealed that trelagliptin is a substrate-competitive, reversible, slow-binding inhibitor (t1/2 for dissociation = ca. 30 min) of DPP-4, although the dissociation time is insufficient to explain its long-acting effects. In a phase III trial, once-weekly trelagliptin (100 mg) showed similar efficacy and safety to once-daily alogliptin (25 mg) in patients with type 2 DM inadequately controlled by diet and exercise. The medicinal chemistry discovery of trelagliptin and alogliptin as well as reviews of this class of compounds have been published.용도
Trelagliptin succinate (SYR-472) is a selective, long acting dipeptidyl peptidase-4 (DPP-4) inhibitor. An antidiabetic agent.Orally active DPP-4 inhibitor that produces clinically and statistically significant improvements in glycaemic control in patients with type 2 diabetes. SYR472 has a long duration of action and is well tolerated in clinical studies.
Clinical Use
Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor used for the treatment of type 2 diabetes mellitus. Trelagliptin (as the salt Trelagliptin succinate) was approved for use in Japan in March 2015. Takeda, the company that developed Trelagliptin, chose to not get approval for the drug in the USA and EU.Trelagliptin succinate 준비 용품 및 원자재
원자재
준비 용품
Trelagliptin succinate 공급 업체
글로벌( 428)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
Huadong Medicine (Xi'an)Bodyguard Pharmaceutical Co.,Ltd. | +86-029-86185165 +8618629664246 |
guoyuan@eastchinapharm.com | China | 1615 | 58 |
Hebei Weibang Biotechnology Co., Ltd | +8615531157085 |
abby@weibangbio.com | China | 8812 | 58 |
Firsky International Trade (Wuhan) Co., Ltd | +8615387054039 |
admin@firsky-cn.com | China | 427 | 58 |
Hangzhou ICH Biofarm Co., Ltd | +86-0571-28186870; +undefined8613073685410 |
sales@ichemie.com | China | 998 | 58 |
Zibo Hangyu Biotechnology Development Co., Ltd | +86-0533-2185556 +8617865335152 |
Mandy@hangyubiotech.com | China | 10986 | 58 |
Shaanxi TNJONE Pharmaceutical Co., Ltd | +8618092446649 |
sarah@tnjone.com | China | 1143 | 58 |
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. | +86-18600796368 +86-18600796368 |
sales@sjar-tech.com | China | 444 | 58 |
Capot Chemical Co.,Ltd. | +86-(0)57185586718 +86-13336195806 |
sales@capot.com | China | 29791 | 60 |
Beijing Cooperate Pharmaceutical Co.,Ltd | 010-60279497 |
sales01@cooperate-pharm.com | CHINA | 1803 | 55 |
Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 |
info@tianfuchem.com | China | 21634 | 55 |
Trelagliptin succinate 관련 검색:
TrifluoroMethyl Dechloro
Imatinib mesylate
Ziconotide Polyacetate
Levobupivacaine hydrochloride
Pregabalin
Calcitonin salmon
Entacapone
Ribonucleic acid
ALOGLIPTIN(ALOGLIPTINE, ALOGLIPTINA)
AGOMELATINE
Linagliptin
Alogliptin benzoate
Vonoprazan fumarate
Teneligliptin Hydrobromide
Trelagliptin Impurity X
(R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzoic acid
Trelagliptin
Trelagliptin Impurity 20